Immune Reconstitution SLE Models

Patient-derived PBMC-NCG SLE model


1.jpeg

  

The levels of serum IgGs


D14 post reconstitution  


2.jpeg


Treating with Blincyto and tri-specific antibody showed inhibition of human anti-dsDNA IgG in SLE model, as well as human total IgG one week after administration,

 

D28 post reconstitution

 

3.jpeg

Blincyto and tri-specific antibody showed inhibition of human anti-dsDNA IgG in SLE model, as well as human IgG three weeks after administration. 

 

Immune cells population


4.png

Blincyto and tri-specific antibody showed depletion of B cells (CD 20+), memory B cells (CD27+) and plasma B cells three weeks after administration.

 

IgG deposition in Kidney  


5.png  

Blincyto and tri-specific antibody showed inhibition of human IgG deposition in SLE model three weeks after administration,

 

 

Induction of SLE model in HSC reconstitution mice


6.jpeg


Serum IgG levels


7.jpeg

HSC-NCG SLE model responded to anti-CD3-CD19 bispecific antibody, anti-CD3-BCMA bispecific antibody and Rituximab with lower of serum anti-DNA IgG levels detected post-treatment.


Immune cells population


D13 FACS of blood

 

8.png

 

D27 FACS of blood

 

9.png

HSC-NCG SLE model responded to anti-CD3-CD19 bispecific antibody, anti-CD3-BCMA bispecific antibody and Rituximab with lower levels of circulating CD3+ and Cd19+ cells detected post-treatment.

 

D27 FACS of spleen

 

10.png

HSC-NCG SLE model responded to anti-CD3-CD19 bispecific antibody, anti-CD3-BCMA bispecific antibody and Rituximab with lower levels of CD3+, Cd19+, T follicular helper cells (TFH), plasma B-cells, plasmablast cells and marginal zone B-cells (MZB) detected post-treatment.

Data request in progress, please wait…